Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.
暂无分享,去创建一个
N. Rogers | J. Pilewski | B. Zuckerbraun | H. Champion | E. Bauer | J. Isenberg | M. Feijóo-Cuaresma | Mingyi Yao | P. Bauer | M. J. Calzada
[1] OlivierFeron,et al. Moderate Caveolin-1 Downregulation Prevents NADPH Oxidase–Dependent Endothelial Nitric Oxide Synthase Uncoupling by Angiotensin II in Endothelial Cells , 2011 .
[2] D. Roberts,et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. , 2010, Cardiovascular research.
[3] R. Khanin,et al. Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[4] Rui Li,et al. Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. , 2010, American journal of respiratory cell and molecular biology.
[5] D. Roberts,et al. Thrombospondin-1/CD47 Blockade following Ischemia-Reperfusion Injury Is Tissue Protective , 2009, Plastic and reconstructive surgery.
[6] Kurt R Stenmark,et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[7] M. Gladwin,et al. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. , 2009, Nitric oxide : biology and chemistry.
[8] A. Malik,et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. , 2009, The Journal of clinical investigation.
[9] D. Mosher,et al. Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses* , 2009, Journal of Biological Chemistry.
[10] C. Schwencke,et al. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. , 2008, Pulmonary pharmacology & therapeutics.
[11] W. Frishman,et al. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[12] M. Toborek,et al. The role of caveolin-1 in PCB77-induced eNOS phosphorylation in human-derived endothelial cells. , 2007, American journal of physiology. Heart and circulatory physiology.
[13] W. Sessa,et al. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice , 2007, The Journal of experimental medicine.
[14] S. Black,et al. The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow. , 2007, American journal of physiology. Heart and circulatory physiology.
[15] P. Insel,et al. Increased smooth muscle cell expression of caveolin‐1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] M. J. Wagner,et al. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. , 2007, Cardiovascular research.
[17] D. Wink,et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. , 2007, Blood.
[18] D. Wink,et al. CD47 Is Necessary for Inhibition of Nitric Oxide-stimulated Vascular Cell Responses by Thrombospondin-1* , 2006, Journal of Biological Chemistry.
[19] B. Y. Chin,et al. Carbon monoxide reverses established pulmonary hypertension , 2006, The Journal of experimental medicine.
[20] S. Archer,et al. An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.
[21] N. Chesler,et al. The Mechanobiology of Pulmonary Vascular Remodeling in the Congenital Absence of eNOS , 2006, Biomechanics and modeling in mechanobiology.
[22] N. Voelkel,et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. , 2006, Chest.
[23] D. Wink,et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] K. Rockett,et al. Pivotal Role for Endothelial Tetrahydrobiopterin in Pulmonary Hypertension , 2005, Circulation.
[25] J. Lawler,et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. , 2005, Matrix biology : journal of the International Society for Matrix Biology.
[26] W. Sessa,et al. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] Y. Fung,et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. , 2004, Microvascular research.
[28] H. Schröder,et al. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action , 2004, British journal of pharmacology.
[29] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[30] W. Sessa. eNOS at a glance , 2004, Journal of Cell Science.
[31] W. Seeger,et al. Clinical classification of pulmonary hypertension. , 2001, Clinics in chest medicine.
[32] H. Farber,et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.
[33] K. Pritchard,et al. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. , 2003, American journal of physiology. Heart and circulatory physiology.
[34] U. Förstermann,et al. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. , 2002, Nitric oxide : biology and chemistry.
[35] J. Ross,et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[36] David S. Park,et al. Caveolin-1-deficient Mice Are Lean, Resistant to Diet-induced Obesity, and Show Hypertriglyceridemia with Adipocyte Abnormalities* , 2002, The Journal of Biological Chemistry.
[37] W. Sessa,et al. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? , 2001, The Journal of pharmacology and experimental therapeutics.
[38] W. Sessa,et al. Distinction between signaling mechanisms in lipid rafts vs. caveolae , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Drab,et al. Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted Mice , 2001, Science.
[40] A. Zeiher,et al. Phosphorylation of the endothelial nitric oxide synthase at Ser‐1177 is required for VEGF‐induced endothelial cell migration , 2000, FEBS letters.
[41] R. Busse,et al. Signal transduction of eNOS activation. , 1999, Cardiovascular research.
[42] W. Sessa,et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt , 1999, Nature.
[43] J. Richalet,et al. Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine. , 1998, The European respiratory journal.
[44] R. Hynes,et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.
[45] H. Ju,et al. Direct Interaction of Endothelial Nitric-oxide Synthase and Caveolin-1 Inhibits Synthase Activity* , 1997, The Journal of Biological Chemistry.
[46] Richard G. W. Anderson,et al. Acylation Targets Endothelial Nitric-oxide Synthase to Plasmalemmal Caveolae (*) , 1996, The Journal of Biological Chemistry.
[47] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[48] C. Pernot. [Pulmonary arterial hypertension]. , 1958, Revue medicale de Nancy.